Livtencity (maribavir) — United Healthcare
post-transplant CMV disease
Initial criteria
- Diagnosis of post-transplant cytomegalovirus (CMV) infection or CMV disease
- AND CMV infection or disease is refractory to treatment (with or without genotypic resistance) to one of the following: ganciclovir, valganciclovir, cidofovir, or foscarnet
- AND Patient is not receiving Livtencity in combination with ganciclovir or valganciclovir
Approval duration
2 months